Infliximab use in Crohn's disease

被引：11

作者：

Bewtra, M ^{[1
]}

Lichtenstein, GR ^{[1
]}

机构：

[1] Univ Penn Hlth Syst, Div Gastroenterol, Philadelphia, PA 19104 USA

来源：

EXPERT OPINION ON BIOLOGICAL THERAPY | 2005年 / 5卷 / 04期

关键词：

Crohn's disease; inflammatory bowel disease; infliximab;

D O I：

10.1517/14712598.5.4.589

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Crohn's disease is a chronic inflammatory disease of the gastrointestinal tract. The disease can be quite severe, resulting in hospitalisation, requiring long-term treatment with a variety of medications and frequent surgeries. Infliximab is a chimeric monoclonal antibody directed against tumour necrosis factor, a key cytokine in the inflammatory cascade of many diseases, including Crohn's disease. Numerous studies have shown significant improvement in both clinical and endoscopic luminal and fistulising Crohn's disease with infliximab treatment. The clinical efficacy, indications, safety profile and future of infliximab are reviewed.

引用

页码：589 / 599

页数：11

共 65 条

[1]

AGGARWAL BB, 1992, TUMOUR NECROSIS FACT

[2] Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease [J].

Baert, F ;

Noman, M ;

Vermeire, S ;

Van Assche, G ;

D'Haens, G ;

Carbonez, A ;

Rutgeerts, P .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (07) :601-608

[3] Tumor necrosis factor α antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis [J].

Baert, FJ ;

D'Haens, GR ;

Peeters, M ;

Hiele, MI ;

Schaible, TF ;

Shealy, D ;

Geboes, K ;

Rutgeerts, PJ .

GASTROENTEROLOGY, 1999, 116 (01) :22-28

[4] THE BIOLOGY OF CACHECTIN/TNF - A PRIMARY MEDIATOR OF THE HOST RESPONSE [J].

BEUTLER, B ;

CERAMI, A .

ANNUAL REVIEW OF IMMUNOLOGY, 1989, 7 :625-655

[5]

Beutler B, 1992, TUMOR NECROSIS FACTO

[6] Integrating anti-tumor necrosis factor therapy in inflammatory bowel disease: Current and future perspectives [J].

Blam, ME ;

Stein, RB ;

Lichtenstein, GR .

AMERICAN JOURNAL OF GASTROENTEROLOGY, 2001, 96 (07) :1977-1997

[7] TUMOR-NECROSIS-FACTOR-ALPHA IN STOOL AS A MARKER OF INTESTINAL INFLAMMATION [J].

BRAEGGER, CP ;

NICHOLLS, S ;

MURCH, SH ;

STEPHENS, S ;

MACDONALD, TT .

LANCET, 1992, 339 (8785) :89-91

[8] Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis -: An open, observational, extension study of a three-month, randomized, placebo-controlled trial [J].

Braun, J ;

Brandt, J ;

Listing, J ;

Zink, A ;

Alten, R ;

Burmester, G ;

Golder, W ;

Gromnica-Ihle, E ;

Kellner, H ;

Schneider, M ;

Sörensen, H ;

Zeidler, H ;

Reddig, J ;

Sieper, J .

ARTHRITIS AND RHEUMATISM, 2003, 48 (08) :2224-2233

[9] Treatment of active ankylosing spondylitis with infliximab:: a randomised controlled multicentre trial [J].

Braun, J ;

Brandt, J ;

Listing, J ;

Zink, A ;

Alten, R ;

Golder, W ;

Gromica-Ihle, E ;

Kellner, H ;

Krause, A ;

Schneider, M ;

Sörensen, H ;

Zeidler, H ;

Thriene, W ;

Sieper, J .

LANCET, 2002, 359 (9313) :1187-1193

[10]

BRENNAN FM, 1989, LANCET, V2, P244

← 1 2 3 4 5 6 7 →